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Muscle weakness and cachexia are significant paraneoplastic syndromes of many 
advanced cancers. Osteolytic bone metastases are common in advanced breast 
cancer and are a major contributor to decreased survival, performance, and quality of 
life for patients. Pathologic fracture caused by osteolytic cancer in bone (OCIB) leads 
to a significant (32%) increased risk of death compared to patients without fracture. 
Since muscle weakness is linked to risk of falls which are a major cause of fracture, we 
have investigated skeletal muscle response to OCIB. Here, we show that a syngeneic 
mouse model of OCIB (4T1 mammary tumor cells) leads to cachexia and skeletal mus-
cle weakness associated with oxidation of the ryanodine receptor and calcium (Ca2+) 
release channel (RyR1). Muscle atrophy follows known pathways via both myostatin 
signaling and expression of muscle-specific ubiquitin ligases, atrogin-1 and MuRF1. We 
have identified a mechanism for skeletal muscle weakness due to increased oxidative 
stress on RyR1 via NAPDH oxidases [NADPH oxidase 2 (Nox2) and NADPH oxidase 
4 (Nox4)]. In addition, SMAD3 phosphorylation is higher in muscle from tumor-bearing 
mice, a critical step in the intracellular signaling pathway that transmits TGFβ signaling 
to the nucleus. This is the first time that skeletal muscle weakness has been described 
in a syngeneic model of OCIB and represents a unique model system in which to study 
cachexia and changes in skeletal muscle.
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inTrODUcTiOn
Breast cancer is the most common cancer in women (1) and frequently metastasizes to bone in 
advanced disease (2). Healthy bone has endocrine functions that are achieved both by active signal-
ing from bone cells such as osteoblasts and osteocytes as well as passive release of cytokines and 
minerals stored in the bone matrix. However, in the tumor–bone microenvironment, breast cancer 
cells secrete factors that stimulate osteoclast-mediated bone resorption. The increased resorption, 
in turn, greatly increases the release of signaling factors from the mineralized matrix, including 
TGFβ. This further promotes cancer cell invasion, growth, and osteolytic factor production to fuel 
a feed-forward vicious cycle that induces more bone destruction (3–6). Increased bone resorption 
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also causes skeletal complications such as bone pain, fractures, 
hypercalcemia, and nerve compression syndromes (6).
Skeletal muscle weakness is a debilitating consequence of 
many advanced malignancies. Muscle is one of the organ systems 
responsive to bone-derived signals. Thus, conditions such as 
osteolytic cancer in bone (OCIB) that disrupt the balance of nor-
mal bone resorption (7, 8) may also have detrimental effects on 
skeletal muscle. We have recently shown that a significant reduc-
tion in skeletal muscle function occurs in mice with osteolytic 
bone metastases from breast, prostate, and lung cancer and in 
multiple myeloma (9).
In normal muscle contraction, the ryanodine receptor calcium 
(Ca2+) release channel (RyR1) is activated, leading to the release 
of Ca2+ from the sarcoplasmic reticulum (SR) and causing muscle 
contraction. Ca2+ is then pumped back into the SR during relaxa-
tion by the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase. 
Physiological oxidation is a normal signaling mediator in skeletal 
muscle whereas pathological oxidation of RyR1 leads to chan-
nel Ca2+ leak and muscle weakness (10, 11). We have previously 
shown that RyR1 oxidation and loss of its stabilizing subunit, 
calstabin1 (also known as FKBP12), is a biochemical signature of 
RyR1 channel Ca2+ leak in OCIB (9). This biochemical signature 
was also present in skeletal muscle samples taken from patients 
with breast cancer that had metastasized to bone, validating the 
clinical importance of our model systems. NADPH oxidase 4 
(Nox4), a constitutively active oxidase and TGFβ target gene, is 
the source of reactive oxygen species in our models of OCIB that 
lead to skeletal muscle weakness. These data collectively describe 
a novel TGFβ-Nox4-RyR1 axis responsible for skeletal muscle 
weakness in OCIB (9).
The studies described above used human tumor cells, which 
made it necessary to perform the experiments in immunocom-
promised mice. Thus, we wondered whether the presence of a 
functional immune system would alter the TGFβ-Nox4-RyR1 axis 
that we identified. The present study addresses this question using 
a syngeneic murine model of breast cancer that is osteolytic in 
bone (4T1 cells). We have found that mice with 4T1 OCIB develop 
profound skeletal muscle weakness and cachexia within 4 weeks 
of tumor cell inoculation to bone. SMAD3 phosphorylation, the 
relative expression of Nox4 mRNA, and Nox4-RyR1 binding 
were higher in muscle from mice with 4T1 OCIB, consistent with 
disruption of the TGFβ-Nox4-RyR1 axis (9). In addition, skeletal 
muscle fiber diameter was reduced, and mRNA expression of the 
atrophy-related muscle-specific ubiquitin ligases, atrogin-1 and 
MuRF1, were higher in mice with OCIB than non-tumor control 
animals. The relative expression of myostatin mRNA, a strong 
mediator of muscle atrophy, was also higher in mice with OCIB. 
These data indicate that a syngeneic model of OCIB shows both 
muscle weakness due to Ca2+ mishandling and activation of a 
muscle atrophy program.
resUlTs
Weight loss in Mice with 4T1 OciB
To investigate skeletal muscle changes in an immune competent 
model of OCIB, we used 4T1 mouse stage IV breast cancer cells 
(12). We inoculated 100,000 cells (non-tumor mice received PBS), 
directly into the right tibia of 5-week old female Balb/c mice. 
Mice with 4T1 cells in bone exhibit osteolytic lesions as detected 
by X-ray (13–15). In our study, we confirmed this result at 4-week 
postinoculation (Figure 1A). We also found that mice with 4T1 
OCIB had progressive weight loss starting at approximately 
14-day postinoculation (Figure 1B). At 4-week postinoculation, 
mice with 4T1 OCIB had lower individual skeletal muscle weights 
measured following dissection. The extensor digitorum longus 
(EDL), tibialis anterior (TA), soleus (SOL), and gastrocnemius 
(Gastroc) muscles were dissected from hindlimb contralateral to 
the site of inoculation and weighed intact (Figure 1C). Mice with 
4T1 OCIB also had lower lean (Figure 1D) and fat (Figure 1E) 
content as measured by dual energy X-ray absorptiometry (DXA). 
Lean and fat mass was measured both as absolute value at 4-week 
postinoculation and as the percentage change over the baseline 
reading (Figures 1D,E).
4T1 Osteolytic Bone lesions cause 
skeletal Muscle atrophy
Because mice with 4T1 OCIB lost lean mass, we investigated 
known mechanisms of skeletal muscle atrophy. Skeletal muscle 
fiber cross-sectional area was lower in mice with 4T1 OCIB 
than in non-tumor control mice (Figure  2A). We measured 
cross-sectional area from H&E stained histological sections 
from the Gastroc muscle dissected from the side contralateral to 
tumor cell inoculation. At least 200 fibers were measured from 
histological sections taken from three samples from each group. 
Mice with 4T1 OCIB also had higher relative mRNA expression 
of myostatin, a strong negative regulator of skeletal muscle mass 
(16), compared to non-tumor controls (Figure 2B). In addition to 
myostatin, we also measured the relative expression of FOXO3a 
and its downstream targets atrogin-1 and MuRF1. The muscle-
specific ubiquitin ligases atrogin-1 and MuRF1 are induced by 
FOXO3a by two distinct mechanisms during skeletal muscle 
atrophy (17–19). We found that the relative mRNA expression of 
FOXO3a, atrogin-1, and MuRF1 were all increased in mice with 
4T1 OCIB compared to non-tumor control mice (Figure 2C).
skeletal Muscle Weakness in Mice with 
4T1 OciB
To determine skeletal muscle function in mice with 4T1 OCIB, 
we measured in  vivo forelimb grip strength over the course of 
the experiment and at 4-week postinoculation we measured 
whole muscle contractility of the excised EDL muscle. Mice with 
4T1 OCIB developed muscle weakness measured by forelimb 
grip strength starting at approximately 3-week postinoculation 
(Figure 3A). Whole muscle contractility of the excised EDL mus-
cle showed lower muscle-specific force in tumor-bearing mice 
compared to non-tumor control animals (Figure  3B). Specific 
force corrects for differences in muscle size between individual 
animals and test groups (20). We also observed higher EDL fati-
gability in mice with 4T1 OCIB. Fatigue was tested by repeated 
whole muscle tetanic stimulation (Figure  3C). Finally, from 
our whole muscle contractility studies we determined the half-
relaxation time of twitch stimulation of the EDL from mice with 
4T1 OCIB. Tumor mice had a slower relaxation time compared 
FigUre 1 | Mouse breast cancer 4T1 osteolytic cancer in bone (OCIB) leads to osteolysis and body weight loss. (a) X-ray analysis revealed large osteolytic lesions 
in mice receiving 4T1 cell via intratibial injection at 4-week postinjection. (B) Body weight loss in mice with 4T1 OCIB (percentage change in total body weight over 
baseline) (n = 10). (c) Weight loss of individual muscles dissected from the lower hindlimb (n = 10) of mice with 4T1 OCIB; extensor digitorum longus (EDL), tibialis 
anterior (TA), soleus (SOL), and gastrocnemius (Gastroc) compared to non-tumor control mice. Dual energy X-ray absorptiometry (DXA) scan revealed loss of both 
(D) lean content and (e) fat content in mice with 4T1 OCIB at 4-week postinjection (n = 10). Data are mean ± SEM, (B) two-way analysis of variance with Bonferroni 
post-test; (c–e) t-test. *p < 0.05, ***p < 0.001, and ****p < 0.0001.
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to non-tumor control mice (Figure 3D) indicating dysfunctional 
Ca2+ handling in muscle.
ryr1 Oxidation in skeletal Muscle of Mice 
with 4T1 OciB
Increased oxidative stress is a characteristic of advanced breast 
cancer (21). Oxidation of RyR1 channels and reduced binding 
of the stabilizing subunit, calstabin1, in skeletal muscle result in 
pathological SR Ca2+ leak that is associated with muscle weakness 
(9–11). Indeed, skeletal muscle RyR1 channels from mice with 
4T1 OCIB were oxidized, nitrosylated, and depleted of calstabin 
compared to non-tumor control mice (Figure  4A). We have 
previously shown that a major source of oxidative stress in OCIB 
is expression of Nox4 (9), a constitutively active Nox protein. 
Nox4 is a TGFβ target gene that is upregulated following the 
release of TGFβ from the bone matrix during OCIB (9). Mice 
with 4T1 OCIB showed higher SMAD3 phosphorylation, indica-
tive of TGFβ signaling, compared to non-tumor control mice 
(Figure 4B). We also found higher relative mRNA expression of 
Nox4 and higher levels of direct Nox4-RyR1 binding compared to 
non-tumor control mice (Figures 4C,D). Our data also indicate 
an upregulation of NADPH oxidase 2 (Nox2) (Figure 4E) which 
could serve as another source of oxidative stress in muscle from 
mice with 4T1 OCIB. Nox2 and Nox4 are both induced in response 
to TGFβ in certain cell types (22), but interestingly, we did not 
observe upregulation of Nox2 mRNA in muscle in our previous 
studies using human tumor cells in athymic nude mice (9). The 
regulation of Nox2 gene expression in muscle represents a differ-
ence between immunocompetent and immunosuppressed mouse 
models of OCIB. Nox2 is thought to predominantly function in 
phagocytes (23) and activity of these cells in athymic nude mice 
may actually be enhanced (24). Thus, the role of Nox2 and Nox4 
in OCIB-induced oxidative stress still needs to be determined.
DiscUssiOn
Muscle weakness and cachexia are significant paraneoplastic 
syndromes of many advanced cancers. In the present study, 
we have investigated skeletal muscle weakness in a syngeneic 
mouse model of OCIB. Primary mouse 4T1 breast cancers are 
highly metastatic, including an affinity for bone, where the 
cells are aggressively osteolytic (14). Inoculating 4T1 tumor 
cells directly into the bone recapitulates the bone destruction 
(Figure  1A), while limiting metastasis to other organs and 
allowing investigation of bone to muscle signaling in the setting 
of OCIB. While we did observe metastases of 4T1 cells to lung, 
FigUre 2 | Skeletal muscle fiber size is lower in mice with 4T1 osteolytic cancer in bone (OCIB). (a) Gastrocnemius muscle fiber diameter was lower in mice with 
4T1 OCIB (n = 3 histological sections) compared to non-tumor control mice. (B) Relative myostatin mRNA expression in tibialis anterior (TA) muscle from non-tumor 
mice and mice with 4T1 OCIB (n = 6). (c) Relative FOXO3, atrogin-1, and MuRF1 mRNA expression in TA muscle from non-tumor mice and mice with 4T1 OCIB 
(n = 6). (a) Data are mean ± SEM, error bars in (B,c) represent ddCt ± SD propagated to fold change, (a–c) t-test. *p < 0.05, **p < 0.01, and ***p < 0.001.
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the number of cells inoculated and the time postinoculation 
were optimized for assessment of skeletal muscle changes in 
response to osteolytic lesion development. Importantly, this 
syngeneic system allows for the study of pathways important 
for changes in both muscle mass and muscle function in animals 
with an intact immune system and mimics the bone destruction 
and bone–muscle crosstalk that occur in humans with breast 
cancer bone metastases (9).
We have previously shown that TGFβ released from the bone 
matrix during osteolysis due to breast cancer bone metastases 
causes oxidative stress and skeletal muscle Ca2+ leak and weak-
ness via the TGFβ-Nox4-RyR1 axis (9). This mechanism was 
elucidated in athymic nude mice to accommodate the use of 
human breast cancer cells (MDA-MB-231, ZR-75-1, and MCF-7), 
human lung cancer cells (RWGT2 and A549), human prostate 
cancer cells (PC-3), and human multiple myeloma cells (JJN-3). 
In addition, mice with MDA-MB-231, MCF-7, A549, or PC-3 
bone metastases also develop cachexia that is independent of the 
reduction in skeletal muscle function.
While our previous studies strongly implicate bone-to-muscle 
signaling as the root cause of the skeletal muscle weakness, we 
felt it was important to investigate whether the presence of a 
functional immune system significantly alters OCIB-driven 
muscle weakness since this represents a major difference between 
the mouse models and human patients. In the present study, we 
have shown that mice with 4T1 OCIB develop both cachexia and 
skeletal muscle weakness. Myostatin expression and activation 
of the ubiquitin ligases atrogin-1 and MuRF1 downstream of 
FOXO3a are hallmarks of skeletal muscle atrophy (16–19) and 
are likely responsible for the cachexia in the 4T1 OCIB model. 
In addition, we determined that these immune competent mice 
display the same biochemical signature of RyR1 oxidation leading 
to skeletal muscle SR Ca2+ leak as immunodeficient mice with 
human tumor cells (9). The TGFβ signal mediator SMAD3 is 
phosphorylated in mice with 4T1 OCIB and that the relative 
expression of Nox4 mRNA and Nox4-RyR1 binding is higher 
than in non-tumor control mice. Overall, these data recapitulate 
those described in athymic nude mice and suggest that immune 
functionality does not significantly alter OCIB-induced cachexia 
or muscle weakness.
MaTerials anD MeThODs
animals
Female Balb/c mice were obtained from Harlan (Indianapolis, 
IN, USA) at 5 weeks of age. All experiments with animals were 
performed at the Indiana University School of Medicine (IUSM) 
and approved by Indiana University’s Institutional Animal Care 
and Use Committee (IACUC).
FigUre 3 | Skeletal muscle weakness in mice with 4T1 osteolytic cancer in bone (OCIB). (a) In vivo forelimb grip strength (n = 10) and (B) excised whole muscle 
contractility of the extensor digitorum longus (EDL) muscle (n = 10) were lower in mice with 4T1 OCIB. (c) Skeletal muscle fatigue was higher in mice with 4T1 cells 
in bone (percent of maximum force) (n = 10). (D) Half-relaxation time (1/2 RT) was higher in EDL from mice with 4T1 OCIB compared to non-tumor control mice. 
Data are mean ± SEM, (a,B,c) two-way analysis of variance with Bonferroni post-test, (D) t-test. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
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ethics statement
In all studies, mice were handled and euthanized in accordance 
with approved institutional and national guidelines set forth 
by the Indiana University IACUC and the Laboratory Animal 
Resource Center at the IUSM. This facility is fully accredited by 
the American Association for the Accreditation of Laboratory 
Animal Care, International and is registered with the USDA as 
a Research Facility.
Materials
Antibodies: Anti-RyR (Affinity Bioreagents, cat. no. MA3-916, 
Golden, CO, USA; 1:2,000), anti-RyR1 5029 (custom rabbit poly-
clonal antibody raised against the C-terminus of human RyR1, 
Yenzyme, South San Francisco, CA, USA; 1:250 for IP), anti-Cys 
NO antibody (Sigma, cat. no. N0409, St. Louis, MO, USA; 1:2,000), 
anti-calstabin antibody (Santa Cruz Biotechnology, cat. no. sc-6173, 
Santa Cruz, CA, USA, 1:2,500), anti-DNP (Oxyblot, cat. no. S7150, 
Millipore, Darmstadt, Germany; 1:250), anti-pSMAD3 (Abcam, 
cat. no. ab40854, Cambridge, UK; 1:1,000), anti-SMAD3 (Abcam, 
cat. no. 52903, Cambridge, UK; 1:1,1000), and anti-Nox4 
(Abcam, cat. no. 109225, Cambridge, UK; 1:1,000).
cell culture
4T1 breast cancer cells (ATCC, CRL-2539, Manassas, VA, USA) 
were cultured in Dulbecco’s modified Eagle’s media (Hyclone, 
Logan, UT, USA) containing 10% heat-inactivated fetal bovine 
serum. Cells were maintained at 37°C with 5% CO2 in a humidi-
fied chamber.
In Vivo Models
Intratibial inoculation of tumor cells was performed on 5-week 
old female Balb/c mice. Tumor cells were trypsinized, washed 
twice in sterile ice cold PBS, and resuspended in ice cold PBS to 
a final concentration of 105 cells in 20 µl. Mice were anesthetized 
(ketamine and xylazine) and inoculated in the proximal tibia 
using a 27-gauge needle. 100,000 cells (or PBS for non-tumor 
controls) were inoculated into the right tibia of each animal. 
Measurements of muscle weight and muscle function were 
done using the hindlimb contralateral to the side of tumor cell 
inoculation.
radiography
The presence of osteolytic lesions was visualized by radiography 
on a Kubtec digital X-ray imager (Kubtec, Milford, CT, USA). 
Mice were placed in a prone position and imaged at 2.7× mag-
nification. The investigators were blinded to treatment subjects.
Dual energy X-ray absorptiometry
Body composition (lean and fat content) was determined using 
a PIXImus mouse densitometer (GE Lunar II, Faxitron Corp., 
Tucson, AZ, USA). Mice were anesthetized and placed with limbs 
spread on an adhesive tray in a prone position. Measurements 
FigUre 4 | Skeletal muscle ryanodine receptor oxidation and SMAD3 phosphorylation are higher in mice with 4T1 osteolytic cancer in bone (OCIB). (a) Immunoblot 
(left) and quantification (right) of RyR1 oxidation (DNP) and nitrosylation (CysNO) and of RyR1-calstabin1 binding, as measured by coimmunoprecipitation, from 
extensor digitorum longus (EDL) muscle (n = 4). RyR1 was oxidized and depleted of calstabin1 in mice with 4T1 OCIB. (B) Immunoblot of SMAD3 phosphorylation 
(left) and quantification (right) from muscle revealed increased phosphorylation in mice with 4T1 OCIB compared to non-tumor control mice (n = 4). (c) Relative 
NADPH oxidase 4 (Nox4) mRNA expression was higher in tibialis anterior (TA) muscle from mice with 4T1 OCIB than in non-tumor control mice (n = 6).  
(D) Immunoblot (left) and quantification (right) of Nox4 coimmunoprecipitation with RyR1 from EDL muscle revealed higher Nox4 interaction with RyR1 in muscle 
from mice with 4T1 OCIB (n = 4). (e) Relative NADPH oxidase 2 (Nox2) mRNA expression was higher in TA muscle from mice with 4T1 OCIB than in non-tumor 
control mice (n = 6). (a,B,D) Data are mean ± SEM, error bars in (c,e) represent ddCt ± SD propagated to fold-change, (a,B,D) t-test. *p < 0.05, **p < 0.01,  
and ****p < 0.0001.
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were performed and analyzed excluding the calvarium, mandible, 
and teeth. Values for lean and fat content were expressed as both a 
final absolute value and as a percentage change over the baseline 
scan. The investigators were blinded to treatment of subjects.
grip strength
Forelimb grip strength was assessed by allowing each mouse to 
grab a wire mesh attached to a force transducer (Bioseb, Vitrolles, 
France) that records the peak force generated as the mouse is 
pulled by the tail horizontally away from the mesh. The investiga-
tors were blinded to treatment of subjects.
Muscle Function
Whole muscle contractility of the EDL muscles was determined 
as previously described (9). EDL was dissected from hind 
limbs, and stainless steel hooks were tied to the tendons of the 
muscles using 4-0 silk sutures, and the muscles were mounted 
between a force transducer (Aurora Scientific, Aurora, ON, 
Canada) and an adjustable hook. The muscles were immersed 
in a stimulation chamber containing O2/CO2 (95/5%) bub-
bled Tyrode solution (121  mM NaCl, 5.0  mM KCl, 1.8  mM 
CaCl2, 0.5  mM MgCl2, 0.4  mM NaH2PO4, 24  mM NaHCO3, 
0.1  mM EDTA, and 5.5  mM glucose). The force–frequency 
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relationships were determined by stimulation of 0.5 ms pulses 
at 1–150 Hz for 350 ms with rest for 3 min between stimula-
tions. Fatigue of the muscle was determined by calculating the 
percentage of maximum force generated at repeated tetanic 
stimulations. To quantify the specific force, the absolute force 
was normalized to the muscle size (20). The half-relaxation 
time was determined during muscle stimulations during 
twitch stimulation. The investigators were blinded to treat-
ment of subjects.
ryr1 immunoprecipitation and 
immunoblotting
RyR1 oxidation and nitrosylation and calstabin1 binding 
were determined from EDL muscles as previously described 
(9). Immunoblots were developed and quantified using the 
Odyssey Infrared Imaging System (LI-COR Biosciences, 
Lincoln, NE, USA) and infrared-labeled secondary antibod-
ies. Detection of Nox4 (Abcam, Cambridge, UK; 1:1,000) was 
from immunoprecipitated RyR1 as described above. Detection 
of pSMAD3, SMAD3 (Abcam, Cambridge, UK; 1:1,000 each), 
and tubulin (Sigma, St. Louis, MO, USA; 1:500 each) from 
mouse muscle was via lysis in NP-40 buffer, and detection 
and quantification of immobilized proteins using the Odyssey 
Infrared Imaging System. The investigators were blinded to 
treatment of subjects.
semi-Quantitative rT-Pcr
Tibialis anterior muscle was lysed by dounce homogenization 
in Trizol (Invitrogen) for RNA extraction. One-fifth volume 
chloroform was added to lysates and vortexed vigorously for 
15 s and incubated at room temperature for 3 min. Samples were 
loaded onto GenElute mammalian total RNA mini columns 
(Sigma). DNase I treatment was performed to remove genomic 
DNA contamination (Qiagen), and RNA integrity was assessed 
on agarose gels. RNA was reverse transcribed using Superscript II 
(Invitrogen) with anchored oligo(dT) (Promega) for priming. The 
cDNAs were prepared for semiquantitative real-time PCR using 
HotStart-IT SYBR Green PCR Kit (Affymetrix) and analyzed in a 
CFX96 Real-Time PCR Detection System (BioRad) for 40 cycles 
(95°C for 15 s, 58°C 30 s, and 72°C for 30°s) after an initial 2 min 
incubation at 95°C. Target gene expression (Nox2 and Nox4), 
FOXO3a, atrogin-1, MuRF1, and myostatin were normalized 
against the housekeeping gene β2-microglobulin (B2M), and data 
were analyzed using the ΔΔCt method. Primers: B2M forward: 
5′-CTG ACC GGC CTG TAT GCT AT-3′; B2M reverse 5′-CAG 
TCT CAG TGG GGG TGA AT-3′; Nox2 forward 5′-CCC TTT 
GGT ACA GCC AGT GAA GAT-3′; Nox2 reverse 5′-CAA TCC 
CGG CTC CCA CTA ACA TCA-3′; Nox4 forward 5′-GGA TCA 
CAG AAG GTC CCT AGC AG-3′; Nox4 reverse 5′-GCG GCT 
ACA TGC ACA CCT GAG AA-3′; FOXO3 forward 5′-CAG 
GCT CCT CAC TGT ATT CAG CTA-3′; FOXO3 reverse 5′-CAT 
TGA ACA TGT CCA GGT CCA A-3′, atrogin-1 forward 5′-GCA 
GAG AGT CGG CAA GTC-3′, atrogin-1 reverse 5′-CAG GTC 
GGT GAT CGT GAG-3′, MuRF1 forward 5′- GCT GGT GGA 
AAA CAT CAT TGA CAT-3′, and MuRF1 reverse 5′-ACT GGA 
GCA CTC CTG CTT GTA GAT-3′.
statistical analysis
The data are presented as mean  ±  SEM. Differences among 
experimental groups were analyzed by t-tests or analysis of 
variance (ANOVA) with appropriate post  hoc and multiple 
comparison tests. For single time point measures of any sample 
size, a two-sided t-test was used (25). When more than two 
groups were compared simultaneously ANOVA, followed by 
Bonferroni post hoc tests, was used (e.g., force–frequency com-
parison between control and tumor bearing groups). p-Values 
less than 0.05 were considered significant (*p < 0.05; **p < 0.01; 
***p <  0.0005; and ****p <  0.0001). Statistical analyses were 
performed with Prism 6.0 software (GraphPad Prism, La Jolla, 
CA, USA). The number of mice required to assess muscle func-
tion in mice with OCIB was determined by power analysis using 
previous data on improvement in muscle function in mice with 
bone metastases. From the mean difference in specific force 
production with OCIB vs vehicle was 42% (275 vs 390  kN/m2) 
with SD = 64 kN/m2. Assuming α error rate = 0.05 and β error 
rate  =  0.20, and a more conservative 30% mean difference 
(275–360), the minimum number of animals per group needed 
is n =  8 for a two-sided Student’s t-test. Based on the experi-
ence of the Investigators, approximately 80% of mice injected 
develop tumors; so 10 mice per group were used. Exclusion plan: 
EDL-specific force data were excluded in cases where there was 
evidence of damage to the muscle fibers. This exclusion plan 
was pre-established. Female Balb/c mice received from Harlan 
(Indianapolis, IN, USA) were randomized into groups upon 
arrival.
eThics sTaTeMenT
In all studies, mice were handled and euthanized in accord-
ance with approved institutional and national guidelines set 
forth by the Indiana University Institutional Animal Care and 
Use Committee and the Laboratory Animal Resource Center 
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(AAALAC) and is registered with the USDA as a Research Facility.
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